Table 3.
Antiretroviral therapy used by HIV-infected patients admitted to the ICU and adverse effects during hospitalization
| Antiretroviral Regimen | Overall (n = 204) |
Patients With ART Beginning Previous ICU Admission (n = 143) |
Patients With ART Beginning During ICU Stay (n = 61)a |
|---|---|---|---|
| 2 NRTI + 1 PI, n (%) | 64 (31.4) | 50 (35.0) | 14 (23.0) |
| 2 NRTI + 1 NNRTI, n (%) | 61 (29.9) | 39 (27.3) | 23 (37.7) |
| 2 NRTI + boosted PI, n (%) | 36 (17.7) | 21 (15.4) | 14 (23.0) |
| 2 NRTI, n (%) | 24 (11.8) | 17 (11.9) | 7 (11.5) |
| Others, n (%) | 19 (9.3) | 16 (11.2) | 3 (4.9) |
| Discontinue/modify ART, n (%) | 43 (21.1) | 33 (23.1) | 10 (16.4) |
| Adverse effects, n (%) | 37 (18.1) | 30 (20.1) | 7 (11.4) |
| Hematologic disorders,b n (%) | 18 (8.8) | 16 (11.9) | 2 (3.3) |
| Acute pancreatitis, n (%) | 4 (2) | 2 (1.4) | 2 (3.3) |
| Lactic acidosis, n (%) | 6 (2.9) | 5 (3.5) | 1 (1.6) |
| Others, n (%) | 6 (2.9) | 4 (2.8) | 2 (3.3) |
NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors, ART, antiretroviral therapy; ICU, intensive care unit.
a
Patients who were already receiving antiretroviral therapy and continued to receive it in the ICU or those who initiated antiretroviral therapy in the ICU;
b
anemia, bicytopenia, and pancytopenia.